ERBB2 and breast cancer: BROCADE3 evaluated the efficacy of veliparib versus placebo when combined with carboplatin and paclitaxel, with monotherapy continuation upon discontinuation of carboplatin and paclitaxel, in HER2-negative advanced BC patients with a gBRCA1/2 mutation.